Swiss Healthtech Stock News

Regulators have confirmed a food poisoning toxin in some Nestlé (SWX:NESN) baby formula products, prompting recalls and investigations that are now central to how investors assess the company’s risk profile and potential reputational overhang. See our latest analysis for Nestlé. The recent baby formula recalls and food safety investigations come after a period where Nestlé’s 30 day share price return of 6.74% decline and 90 day share price return of 4.49% decline have weighed on sentiment,...

In January 2026, Huber+Suhner AG reported unaudited 2025 net sales of CHF 864.1 million, compared with CHF 893.9 million in the prior year. At the same time, the company confirmed guidance for a 2025 operating profit margin of 10–11%, suggesting a focus on maintaining profitability despite slightly lower sales. We will now examine how the confirmed 10–11% EBIT margin guidance shapes Huber+Suhner’s investment narrative following these latest results. We've found 14 US stocks that are...

Roche Holding (SWX:ROG) is in focus after reporting full year 2025 earnings alongside standout Phase II data for its obesity candidate CT-388 and proposing a higher dividend, a combination that sharpens attention on its cardiometabolic ambitions. See our latest analysis for Roche Holding. The latest CT-388 data and dividend proposal come after a strong run in the share price, with a 90 day share price return of 35.46% and a 1 year total shareholder return of 26.68%. This suggests momentum has...

Why BELIMO Holding’s latest sales update matters for investors BELIMO Holding (SWX:BEAN) has drawn fresh attention after reporting 2025 revenue of CHF 1,121 million, with sales growth of 23.3% year-on-year in local currencies, compared with 13.1% in 2024. See our latest analysis for BELIMO Holding. The latest sales update arrives as BELIMO Holding’s share price trades at CHF 845.0, with a 30‑day share price return of 8.19% and a 1‑year total shareholder return of 28.44%. This suggests...

Amrize has announced it will release its fourth-quarter 2025 results after the U.S. market closes on February 17, 2026, followed by a webcast the next morning to discuss the numbers with investors. Fresh analyst coverage, including updated ratings and commentary, is sharpening market attention on how these upcoming results could shape perceptions of Amrize’s outlook. We’ll now examine how the upcoming fourth-quarter earnings release and related analyst commentary may influence Amrize’s...

If you are wondering whether Adecco Group is offering good value at its current share price, this article walks through the key numbers that matter to you as an investor. The stock last closed at CHF 22.62, with a 7 day return of a 0.4% decline and a 30 day return of a 2.2% decline, while the 1 year return sits at 8.6% and the 3 year and 5 year returns are 24.9% and 46.3% declines respectively. These mixed returns arrive as Adecco continues to sit in the spotlight of long term themes such as...

How ABB (SWX:ABBN)'s FY 2025 Numbers Set the Stage ABB (SWX:ABBN) closed FY 2025 with fourth quarter revenue of US$9.1b and basic EPS of US$0.70, alongside trailing twelve month revenue of US$33.2b and EPS of US$2.50 that frame the full year picture. Over recent periods, the company has seen quarterly revenue range from US$7.9b to just over US$9.0b and EPS move from US$0.54 in Q4 2024 through to US$0.70 in Q4 2025, giving investors a clear read on how the top line and per share earnings have...

There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...

Key Insights The projected fair value for SKAN Group is CHF46.21 based on 2 Stage Free Cash Flow to Equity SKAN Group...

It's nice to see the Highlight Event and Entertainment AG ( VTX:HLEE ) share price up 11% in a week. But spare a...

Why Kuehne + Nagel International Is On Investors’ Radar Today Kuehne + Nagel International (SWX:KNIN) has drawn attention after recent share performance, with the stock showing mixed returns across different time frames and fresh financial figures that give investors more to work with. The shares are up around 0.6% over the past day and roughly 4.4% over the past month, while the past 3 months show a gain of about 16%. Over 1 year, however, the total return sits near a 9.9% decline, and over...

Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...

At the 2026 World Economic Forum in Davos, Novartis Chairman Dr. Giovanni Caforio announced a past AI- and data-driven national cardiovascular disease prevention partnership with Brunei’s Ministry of Health and EVYD Technology, while Novartis also unveiled a prostate cancer awareness campaign with the NFL built around a “Relax, it’s a blood test” Super Bowl commercial. Together, these initiatives position Novartis as a healthcare innovator using large-scale data, artificial intelligence and...

Why BKW’s new guidance matters now BKW (SWX:BKW) updated investors with two key signals: a lowered EBIT range of CHF 540 million to CHF 560 million for 2025, and a new 2026 EBIT outlook of CHF 650 million to CHF 750 million. See our latest analysis for BKW. The revised guidance appears to have weighed on sentiment, with the share price at CHF145.9 after a 1 day share price return of 1.15% decline and a 30 day share price return of 13.36% decline. The 5 year total shareholder return of 49.78%...

How Givaudan's FY 2025 Results Line Up With the Market Narrative Givaudan (SWX:GIVN) has wrapped up FY 2025 with second half revenue of CHF 3.6b and basic EPS of CHF 51.90, alongside net income of CHF 479m, setting a clear marker for how the year finished operationally. The company has seen revenue move from CHF 3.7b and EPS of CHF 54.41 in the second half of 2024 to CHF 3.9b and EPS of CHF 64.18 in the first half of 2025, before landing at CHF 3.6b and EPS of CHF 51.90 in the latest period,...

Why Julius Bär Gruppe (SWX:BAER) Is Back in Focus Julius Bär Gruppe (SWX:BAER) is under fresh investor scrutiny after client related shocks, tighter risk controls, and higher regulatory pressure started to weigh on sentiment and day to day operations. See our latest analysis for Julius Bär Gruppe. Against this backdrop of client shocks and tighter risk controls, Julius Bär Gruppe’s share price has settled at CHF64.62, with a 90 day share price return of 19.23% contrasting with a slightly...

If you are wondering whether Swatch Group shares still offer value after recent moves, this article walks through what the current price could be saying about the stock. The share price last closed at CHF 183.00, with returns of 10.2% over 7 days, 8.8% over 30 days, 6.4% year to date, 11.4% over 1 year, and longer term returns of 38.7% decline over 3 years and 23.1% decline over 5 years. Recent news around Swatch Group has largely focused on the broader watch and luxury goods sector,...

Lonza Group (SWX:LONN) opened FY 2025 with first half revenue of CHF3.6b and basic EPS of CHF6.08, anchored by net income of CHF426m, setting the tone for how investors will read the rest of the year’s earnings story. The company has seen revenue move from CHF3.1b and EPS of CHF4.61 in the first half of 2024 to CHF3.5b and CHF4.32 in the second half of 2024, before reaching CHF3.6b and CHF6.08 in the first half of 2025. This progression gives investors a clear view of how the top line and EPS...

Nestlé has recalled multiple batches of its SMA baby formula after regulators confirmed contamination with the food poisoning toxin cereulide traced to a shared third-party ingredient supplier, prompting investigations in France into possible links with two infant deaths. Beyond the immediate product recall, the episode highlights how dependence on external suppliers can expose even large food companies to heightened operational and reputational risk. We will now examine how these food...

What UBS Group’s recent performance data tells you UBS Group (SWX:UBSG) has drawn investor attention after a mixed spell, with a small 1 day decline and a negative move over the past week, while the past 3 months show a positive total return. Over the past year, UBS Group’s total return stands at 16.6%, with a 3 year total return around 2x and a 5 year total return a little over 3x. This highlights a longer term recovery profile for shareholders. See our latest analysis for UBS Group. Recent...

Adecco Group (SWX:ADEN) has agreed to acquire Advantis Medical Staffing. The deal expands Adecco’s presence in North American healthcare staffing. Advantis adds travel nursing and allied health capabilities to Adecco’s portfolio. The acquisition focuses Adecco more on healthcare as a critical talent segment. Adecco Group, a global provider of HR and workforce solutions, is deepening its focus on healthcare staffing through the purchase of Advantis Medical Staffing. Advantis brings a...

Why ABB’s latest earnings and AI exposure matter now ABB (SWX:ABBN) has jumped onto many watchlists after reporting fourth quarter 2025 results ahead of forecasts, winning more than US$10b in new orders, and highlighting benefits from rising AI driven data centre demand. See our latest analysis for ABB. The 8.46% 1 day share price return and 11.56% 7 day share price return at CHF66.38 suggest momentum has picked up quickly around the earnings beat and new US$2b buyback. At the same time, the...

Roche Holding AG recently reported 2025 results showing sales of CHF 61,516 million and net income of CHF 12,880 million, while also advancing its obesity pipeline with strong Phase II data for CT-388 indicating significant placebo-adjusted weight loss and a generally tolerable safety profile. Alongside proposing a higher CHF 9.80 dividend for what would be a 39th consecutive increase, Roche issued 2026 guidance for mid single digit Group sales growth and high single digit core EPS growth at...

EPIC Suisse's (VTX:EPIC) stock up by 6.2% over the past three months. However, its weak financial performance...